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Abstract
Objective: Adipose tissue dysfunction, characterized by
dysregulation of adipokines production and/or secretion,
has been implicated in the pathophysiology of type-2
diabetes mellitus, a metabolic complication closely relat-
ed to gestational diabetes mellitus (GDM). Recently, an
association between circulating maternal visfatin, a novel
adipokine with metabolic and immunoregulatory proper-
ties, and impaired glucose metabolism as well as with
altered fetal growth, has been proposed. The aims of this
study were to determine whether there is an association
between maternal plasma visfatin concentration, GDM,
and a large-for-gestational-age (LGA) newborn.
Study design: This cross-sectional study, included preg-
nant women at term in the following groups: 1) normal
pregnancy and an appropriate-for-gestational-age (AGA)
neonate (ns54); 2) normal pregnancy and an LGA new-
born (ns47); 3) GDM and an AGA newborn (ns56); 4)
GDM and an LGA newborn (ns45). The study population
was further stratified by first trimester BMI (-25 vs.
G25 kg/m2). Maternal plasma visfatin concentration was
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determined by ELISA. Parametric and non-parametric
statistics were used for analysis.
Results: 1) Among women who delivered an AGA neo-
nate, the median maternal plasma concentration of vis-
fatin was higher in patients with GDM than in those with
a normal pregnancy; 2) Among women with a normal
pregnancy, those who delivered an LGA neonate had a
higher median maternal plasma visfatin concentration
than those who delivered an AGA neonate; 3) among
patients with normal BMI, there were no significant dif-
ferences in the median maternal plasma visfatin concen-
tration between the four study groups; and 4) maternal
GDM, as well as delivery of an LGA neonate were inde-
pendently associated with a higher maternal plasma
visfatin concentrations.
Conclusion: The linkage between increased maternal
circulating visfatin and the presence of GDM or delivery
of an LGA neonate supports the hypothesis that pertur-
bation of adipokines homeostasis may play a role in the
pathophysiology of GDM or excess fetal growth.
Keywords: adipokine; adipose tissue; appropriate-for-
gestational-age (AGA); gestational diabetes mellitus
(GDM); large-for-gestational-age (LGA); pre-B cell colo-
ny-enhancing factor (PBEF); visfatin.
Introduction
Pregnancy is a unique condition characterized by tran-
sient physiologic insulin resistance w21, 24, 25, 30–32,
58, 65, 105, 109, 114, 158, 167, 177x which progresses
with advancing gestation and approaches that of non-
pregnant patients with type-2 diabetes mellitus (DM) w18x.
Teleologically, this physiological adaptation is aimed to
facilitate delivery of nutrients to the fetus w104, 165x. The
implicit paradigm that has been governed the under-
standing of the metabolic adaptation during pregnancy,
was that insulin resistance should be attributed to the
‘‘diabetogenic’’ effect of placental hormones, such as
human placental lactogen (hPL), estrogen, and proges-
terone. Indeed, both in vivo and in vitro studies support
this view w11, 13, 41, 90, 91, 159, 166, 169x. However,
during the last decade, with the recognition of adipose
tissue as an active endocrine organ, an alternative par-
adigm for the pathogenesis of insulin resistance has
emerged w12, 51, 77, 78, 155, 186, 190x. Indeed, a solid
body of evidence supports the central role of adipose
tissue in the regulation of energy homeostasis as well as
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in metabolism and inflammation in pregnant and non-
pregnant subjects w8, 9, 28, 51, 68, 83, 88, 89, 93, 99,
118, 126, 128, 136, 162–164, 178, 185, 187, 194x.
Visfatin is a 52 kDa adipokine, which is preferentially
produced by visceral adipose tissue w63, 82, 174x and
corresponds to the previously identified growth factor for
early B cell, termed pre-B cell colony-enhancing factor
(PBEF) w86, 124, 149, 170, 198x. Recently, the metabolic
effects of visfatin have been highlighted. Indeed, in vitro,
adipocytes exposure to glucose increased their secretion
of this adipokine w73x. Moreover, visfatin exerts insulin-
like activity as a growth factor for osteoblasts w195x. Plas-
ma concentrations of visfatin are higher in patients with
type-2 DM w36, 53, 116, 171x as well as in obesity w19,
35, 55, 56, 72, 87, 171, 203x than in normal subjects, and
have a positive correlation with body mass index (BMI)
w19, 35, 113, 171x and waist-to-hip ratio w36x. Collective-
ly, these data suggest that visfatin has a role in the phy-
siology and pathophysiology of glucose metabolism.
Only a handful of studies have addressed the maternal
concentration of visfatin in human pregnancy w34, 50, 52,
71, 101, 112, 120, 121, 125x. Furthermore, data regarding
circulating maternal concentrations of visfatin in patients
with gestational diabetes mellitus (GDM) are both scarce
and conflicting. Indeed, maternal visfatin concentrations
(plasma/serum) were reported to be higher w101, 112x
and lower w34, 71x in patients with GDM than in normal
pregnant women. Interestingly, maternal plasma concen-
trations of visfatin are significantly elevated in patients
with fetal growth restriction than in those with an appro-
priate-for-gestational-age (AGA) neonate. Thus, the aims
of this study were to determine whether there is an asso-
ciation between maternal plasma visfatin concentration,
GDM, and a large-for-gestational-age (LGA) newborn.
Materials and methods
A cross-sectional study was conducted by searching our clinical
database and bank of biological samples, and includedpregnant
women at term in the following groups: 1) normal pregnant wom-
en who delivered an AGA newborn (ns54); 2) normal pregnant
women who delivered an LGA newborn (ns47); 3) women with
GDM who delivered an AGA newborn (ns56); and 4) women
with GDM who delivered an LGA newborn (ns45). Women with
multiple pregnancies or fetal congenital anomalies were
excluded.
All women provided written informed consent prior to the col-
lection of maternal blood samples. The utilization of samples for
research purposes was approved by the institutional review
boards of Wayne State University, Sotero del Rio Hospital and
the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD/ NIH/DHHS). Many of these
samples have been previously employed to study the biology of
inflammation, hemostasis, and growth factor concentrations in
normal pregnant women, and those with pregnancy
complications.
Definitions
The inclusion criteria for normal pregnancy were: (1) no medical,
obstetrical or surgical complications; (2) intact membranes; (3)
delivery of a term neonate ()37 weeks) with a birth weight
above the 10th percentile; w7x and (4) a normal oral 75-g oral
glucose tolerance test (OGTT) between 24–28 weeks of gesta-
tion based on World Health Organization (WHO) criteria w3, 6x.
All women underwent a 75-g OGTT between 24 and 28 weeks
of gestation. Diagnosis of GDM was based on the World Health
Organization (WHO) criteria of fasting plasma glucose G126
mg/dL (G7.0 mmol/L) or plasma glucose G140 mg/dL
(G7.8 mmol/L) two hours after the 75-g OGTT w3, 6x. GDM
patients were treated with diet. LGA newborn was defined as an
infant with birth weight above the 90th percentile w7, 69x. The first
trimester BMI was calculated according to the following formula:
weight (kg)/height (m)2 and patients were classified according to
the definitions of the WHO w2x. A normal weight was defined as
BMI between 18.5 and 24.9 kg/m2 and overweight/obese as BMI
G25 kg/m2.
Sample collection
Maternal blood samples were collected at clinical visit. The ges-
tational ages of sample collection were G37 weeks for all
women included in the study. Blood was centrifuged at 1300=g
for 10 min at 48C. The plasma obtained was stored at –808C
until analysis.
Human visfatin C-terminal immunoassay
Concentrations of visfatin in maternal plasma were determined
using specific and sensitive enzyme immunoassays purchased
from Phoenix Pharmaceuticals, Inc (Belmont, CA, USA). Visfatin
C-terminal assays were validated in our laboratory for using
human plasma prior to the conduction of this study. Validation
included spike and recovery experiments, which produced par-
allel curves indicating that maternal plasma matrix constituents
did not interfere with antigen-antibody binding in this assay sys-
tem. Visfatin enzyme immunoassays are based on the principle
of competitive binding and were conducted according to rec-
ommendation of the manufacturer. Briefly, assay plates are pre-
coated with a secondary antibody and the non-specific binding
sites have been blocked. Standards and samples were incubat-
ed in the assay plates along with primary antiserum and bioti-
nylated peptide. The secondary antibody in the assay plates
bound to the Fc fragment of the primary antibody whose Fab
fragment competitively bound with both the biotinylated peptide
and peptide standard or targeted peptide in the samples. Fol-
lowing incubation, the assay plates were repeatedly washed to
remove unbound materials and incubated with a streptavidin-
horseradish peroxidase (SA-HRP) solution. Following incubation,
unbound enzyme conjugate was removed by repeated washing
and a substrate solution was added to the wells of the assay
plates and color developed in proportion to the amount of bio-
tinylated peptide-SA-HRP complex but inversely proportional to
the amount of peptide in the standard solutions or the samples.
Color development was stopped with the addition of an acid
solution and the intensity of color was read using a program-
mable spectrophotometer (SpectraMax M2, Molecular Devices,
Sunnyvale, CA, USA). Maternal plasma concentrations of visfatin
C were determined by interpolation from individual standard
curves composed of human visfatin peptide. The calculated
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Table 1 Clinical and demographic characteristics of the study population.
Normal Normal GDM GDM
pregnancy pregnancy AGA neonate LGA neonate
AGA neonate LGA neonate (ns56) (ns45)
(ns54) (ns47)
Maternal age (years)*, 27 (22–30) 28 (22–32) 32 (24–36) 30 (25–35)
BMI (kg/m2)*,,§ 23 (22–25) 24 (22–28) 26 (22–29) 27 (23–32)
BMI G25 17 (31.4%) 21 (44.6%) 36 (64.2%) 30 (66.6%)
Gestational age at blood sampling (weeks) 39 (38–40) 39 (38–40) 38 (38–40) 38 (38–39)
Gestational age at delivery (weeks) 39 (38–40) 39 (38–40) 39 (38–40) 38 (38–39)
Birth weight (g),&,$,‡ 3390 (3150–3612) 4170 (4050–4415) 3455 (3235–3717) 4190 (4030–4410)
*P-0.05 – Normal pregnancyqAGA vs. GDMqAGA, P-0.05 – Normal pregnancyqAGA vs. GDMqLGA, §P-0.05 – Normal
pregnancyqLGA vs. GDMqLGA, &P-0.05 – Normal pregnancyqAGA vs. Normal pregnancyqLGA, $P-0.05 – GDMqAGA vs.
Normal pregnancyqLGA, ‡P-0.05 – GDMqAGA vs. GDMqLGA.
Values are expressed as median (IQR) or as number (percentage); AGA, appropriate for gestational age; LGA, large for gestational
age; GDM, gestational diabetes mellitus; BMI, body mass index.
inter- and intra-assay coefficients of variation for Visfatin C-ter-
minal immunoassays in our laboratory were 5.3% and 2.4%,
respectively. The sensitivity was calculated to be 0.04 ng/mL.
Statistical analysis
The Shapiro-Wilk and Kolmogorov-Smirnov tests were used to
test for normal distribution of the data. Data are presented as
median and interquartile range (IQR). Non-parametric methods
were used to perform the statistical analysis for parameters
which were not normally distributed and comparisons among
groups were performed using the Kruskal-Wallis test with post
hoc test by Mann-Whitney U-test. Parametric tests were used
for analysis of those parameters that were normally distributed
and the comparisons among groups were performed using one-
way ANOVA with Bonferroni adjustment for the calculated P-
value in order to maintain the significance level at 0.05. Multiple
linear regression analysis was used to determine which factors
were significantly and independently correlated with maternal
plasma visfatin concentration (after log transformation). The fol-
lowing parameters were included in the model: maternal age,
maternal BMI, gestational age at blood collection, GDM and
LGA. The statistical package employed was SPSS 14 (SPSS
Inc., Chicago, IL, USA). A P-value of -0.05 was considered
statistically significant.
Results
The clinical and demographic characteristics of the study
groups are presented in Table 1. Patients with GDM and
an AGA neonate (Ps0.01) or those with GDM and an
LGA neonate (P-0.01) had a higher median maternal
age than normal pregnant women with an AGA neonate.
Maternal plasma visfatin concentration in women
with a normal pregnancy
Visfatin was detected in the plasma of all subjects. There
was a significant difference in the median maternal plas-
ma visfatin concentration among the groups (Ps0.006,
Kruskal-Wallis).
Among women with a normal pregnancy, those with
an LGA neonate had a higher median maternal plasma
visfatin concentration than those with an AGA neonate
(LGA 19.5 ng/mL, IQR 16.2–22.0 vs. AGA 16.6 ng/mL,
IQR 12.2–19.7, P-0.01; Figure 1). Among women who
delivered an AGA neonate, the median maternal plasma
concentration was higher in patients with GDM than
those with a normal pregnancy (GDM: 18.3 ng/mL, IQR
15.9–22.0 vs. normal pregnancy 16.6 ng/mL, IQR
12.2–19.7, Ps0.01; Figure 1).
Maternal plasma visfatin concentration in women
with gestational diabetes mellitus
Patients with GDM who delivered an LGA neonate had a
higher median maternal plasma visfatin concentration
than those with a normal pregnancy and an AGA neonate
(GDMqLGA 19.7 ng/mL, IQR 16.2–23.1 vs. normal
pregnancyqAGA 16.6 ng/mL, IQR 12.2–19.7, P-0.01;
Figure 1). There were no significant differences in the
median maternal plasma visfatin concentration in women
with a normal pregnancy and an LGA neonate and
patients with GDM who delivered either an LGA or AGA
neonate (Ps0.9 and Ps0.3, respectively; Figure 1).
Patients with GDM who delivered an AGA (Ps0.002)
or an LGA neonate (P-0.001) had a higher median
maternal BMI than those with a normal pregnancy and
an AGA neonate. Similarly, patients with GDM and an
LGA neonate (Ps0.02) had a higher median maternal
BMI than those with a normal pregnancy and an LGA
neonate (Table 1). The rate of overweight/obese women
was higher in patients with GDM who delivered an LGA
neonate than in those with a normal pregnancy who
delivered an AGA neonate (Ps0.03).
Maternal plasma visfatin concentration in
normal and overweight/obese pregnant women
with a normal pregnancy
Among overweight/obese women with a normal preg-
nancy, those with an LGA neonate had a higher median
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Figure 1 Comparison of the median maternal plasma visfatin concentrations between women with and without GDM and/or an
LGA fetus.
The median maternal plasma visfatin concentration was higher in patients with GDM, either with an AGA or with LGA fetus, than that
of those with a normal pregnancy and an AGA fetus. Likewise, pregnant women with a normal pregnancy and an LGA fetus had a
higher median maternal plasma visfatin concentration than those with a normal pregnancy and an AGA fetus.
maternal plasma visfatin concentration than those with
an AGA neonate (LGA: 18.8 ng/mL, IQR: 16.5–22.4 vs.
normal AGA 13.7 ng/mL IQR 10.4–19.6, Ps0.003; Figure
2); however, such difference was not detected among
women with a normal weight (Ps0.12).
Maternal plasma visfatin concentration in normal
and overweight/obese pregnant women with
gestational diabetes mellitus
Overweight/obese patients with GDM, either with an AGA
(17.9 ng/mL, IQR: 15.4–22.3) or an LGA neonate
(18.1 ng/mL, IQR: 15.0–22.4), had a higher median
maternal plasma visfatin concentration than overweight/
obese women with a normal pregnancy who delivered an
AGA neonate (13.7 ng/mL, IQR 10.4–19.6; Ps0.01 and
Ps0.03, respectively; Figure 2); however, such differenc-
es were not observed when normal weight patients with
GDM, either with an AGA or an LGA neonate, were com-
pared to normal weight women with a normal pregnancy
and an LGA neonate (Ps0.96 and Ps0.29, respectively).
In addition, among normal weight women with GDM,
there was no significant difference in the median mater-
nal plasma visfatin concentration between those who
delivered an AGA and those who delivered an LGA neo-
nate (Ps0.43).
In order to further study the association between
maternal plasma visfatin concentration and possible con-
founding factors, a multiple linear regression analysis
was performed. Gestational diabetes mellitus (Ps0.03)
and the delivery of an LGA neonate (Ps0.008) were inde-
pendently associated with higher maternal plasma vis-
fatin concentrations after correction for first trimester
maternal BMI, maternal age, and gestational age at blood
collection (Table 2).
Discussion
Principal findings of the study
1) Among women who delivered an AGA neonate, the
median maternal plasma concentration of visfatin was
higher in patients with GDM than in those with a normal
pregnancy; 2) among women with a normal pregnancy,
those who delivered an LGA neonate had a higher medi-
an maternal plasma visfatin concentration than those
who delivered an AGA neonate; 3) among patients with
normal BMI, there were no significant differences in the
median maternal plasma visfatin concentration between
the four study groups; and 4) GDM, as well as delivery
of an LGA neonate were independently associated with
higher maternal plasma visfatin concentrations.
Visfatin is a novel adipokine with metabolic and
immunoregulatory properties Visfatin, a highly con-
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Figure 2 Comparison of the median maternal plasma visfatin concentrations between normal and overweight/obese pregnantwom-
en, with and without GDM and/or an LGA fetus.
Among overweight/obese patients, the median maternal plasma visfatin concentration was significantly higher in patients with GDM,
either with an AGA or with LGA fetus, than that of those with a normal pregnancy and an AGA fetus. Likewise, overweight/obese
pregnant women with a normal pregnancy and an LGA fetus had a higher median maternal plasma visfatin concentration than those
with a normal pregnancy and an AGA fetus. In contrast, there was no significant difference in the median maternal plasma visfatin
concentration among pregnant women with normal weight. Within each study group, the median maternal plasma visfatin concen-
tration was comparable between normal and overweight/obese pregnant women.
Table 2 Linear regression analysis of factors associated with
maternal plasma visfatin concentrations.
Factor Beta Significance
Delivery of LGA neonate 0.193 0.008
GDM 0.174 0.032
Maternal BMI –0.120 0.115
Gestational age at blood collection 0.106 0.154
Maternal age 0.027 0.728
LGA, large for gestational age; GDM, gestational diabetes mel-
litus; BMI, body mass index.
served 52 kDa molecule, was originally cloned in 1994
from human peripheral blood lymphocytes w170x, and its
homologous proteins have been reported in bacteria
w123x, invertebrate w138x, fish w61x and mammals w94,
124, 127, 142, 143, 148–151, 170, 198x. This adipokine
enhances the effect of IL-7 and stem cell factor on pre-
B-cell colony formation, hence it was named pre-B-cell
enhancing factor (PBEF) w170x. Recently, visfatin/PBEF
was reported to be produced by adipose tissue w19, 38,
60, 75, 173, 174x, thus included in the growing family of
adipokines. While preferentially produced by visceral fat
depot w82, 174, 184x, the expression of visfatin is not
limited to adipose tissue. Indeed, it can be expressed in
placenta, fetal membranes w95, 124, 142, 143, 148–151x,
myometrium w48x, bone marrow, liver, muscle w170x,
heart, lung, kidney w170x, macrophages w43x, and neutro-
phils w86, 170, 198x.
The physiologic role of visfatin in humans has not been
fully elucidated; however, it has been proposed that this
adipokine has a regulatory role in glucose metabolism
and inflammation. The following features about visfatin
suggest that this protein has a regulatory role in glucose
homeostasis: 1) in vitro, adipocytes secrete visfatin in
response to glucose exposure w73x; 2) administration of
glucose to human subjects results in increase circulating
visfatin concentration w73x; 3) obesity is associated with
increased circulating visfatin concentration w19, 35, 55,
56, 72, 87, 171, 203x, and plasma concentrations of this
adipokine are positively correlated with BMI w19, 35, 113,
171x and waist-to-hip ratio w36x; 4) consistent with the
aforementioned reports, serum concentration of visfatin
in humans are positively correlated with the amount of
intra-visceral fat as determined by computerized tomo-
graphy scan w171x; 5) plasma concentrations of visfatin
are higher in patients with type-2 DM w36, 53, 116, 171x
or metabolic syndrome w55, 56x than in normal subjects;
and 6) a visfatin promoter polymorphism is associated
with a susceptibility to type-2 DM w204x.
Evidence in support of the immunoregulatory effects of
visfatin includes: 1) the production of proinflammatory
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cytokines (e.g., IL-6, TNF-a, IL-1b) by human mono-
cytes, is up-regulated by visfatin in a dose dependent
manner w137x; 2) the expression of visfatin is increased
following exposure to proinflammatory mediators such as
TNF-a (in monocytes w43x, macrophages w84x and neu-
trophils w86x), IL-6 (synovial w144x and amniotic epithelial
cells w148x) and IL-8 and granulocyte/macrophage colony
stimulating factor (in neutrophils w86x); 3) visfatin expres-
sion is increased in cells retrieved by bronchoalveolar
lavage from patients with acute lung injury w198x and from
lung tissue of animal models of acute lung injury w199x;
similarly, its expression increases in neutrophils from
septic patients w86x; 4) polymorphisms in the visfatin
gene are associated with an increased (–1001G) or
decreased (–1543T) risk of developing ARDS in septic
shock patients than wild-type homozygotes w10x; and 5)
patients with chronic inflammatory disorders such as
inflammatory bowel disease w137x and rheumatoid arthri-
tis w153x have higher circulating visfatin than normal
subjects.
Adipose tissue dysfunction: a novel mechanism of
disease for gestational diabetes mellitus Incapacity
of the adipose tissue to meet the metabolic demands has
been suggested as a putative mechanism of disease for
type-2 DM w67, 106x. According to this hypothesis, one
of the core components of adipose tissue failure is
impaired production and/or secretion of adipokines.
Indeed, several lines of evidence support a causality link-
age between dysregulation of adipokines and type-2 DM:
1) mice deficient in adiponectin w103, 119, 140, 196x, lep-
tin w39, 80x, or TNF-a w189x have insulin resistance; in
addition, the administration of leptin w26, 74, 156x, adi-
ponectin w16, 59, 196x or neutralization of resistin w181x
corrects insulin resistance in obese and diabetic mice; 2)
polymorphisms at the locus of adiponectin w57, 70, 76,
81, 110, 132, 139, 182x, resistin w131, 152x, visfatin w204x,
or leptin receptor w168x are associated with insulin resis-
tance and type-2 DM; and 3) patients with type-2 DM
have a higher plasma concentrations of resistin w62, 129,
202x, TNF-a w44, 135x, RBP-4 w37, 197x, CRP w54, 160x
and a lower concentrations of adiponectin w79, 97, 160,
191x, than normal subjects.
Gestational diabetes mellitus is defined as a carbohy-
drate intolerance of varying severity, with onset, or first
recognition during pregnancy w1, 27, 64, 65, 134, 147x.
This adverse metabolic state affects 1–10% of all preg-
nancies w4, 5, 14, 22, 27, 29, 45, 65, 66, 109, 147x, and
is associated with maternal, fetal and neonatal compli-
cations w5, 15, 17, 20, 23, 33, 40, 42, 45, 47, 85, 96, 100,
133, 141, 145, 146, 157, 172, 179, 180x . Similarly to type-
2 DM, adipose tissue failure, characterized by altered
maternal circulating concentration of adipokines (e.g.,
TNF-a w49, 78, 107, 154, 161, 186, 190, 201x, CRP w128x,
leptin w9, 93, 99, 128x and adiponectin w9, 98, 162, 185,
192, 194x), has been implicated in the pathophysiology
of GDM. Indeed, during pregnancy, maternal serum con-
centrations of several adipokines are correlated with clin-
ical indices of insulin resistance (e.g., HOMA) w28, 99,
118, 128, 163x. Moreover, women with low circulating
adiponectin concentrations w192x or high circulating con-
centrations of CRP w176, 193x during early pregnancy are
more likely to develop GDM than those with normal con-
centrations of these adipokines. Collectively, these find-
ings suggest that adipokines play a role in the
pathophysiology of GDM.
Visfatin in human pregnancy There are only few
reports regarding circulating visfatin concentrations in
pregnant women w34, 50, 52, 71, 101, 112, 120, 121,
125x. Mastorakos et al. w125x conducted a longitudinal
study in which maternal serum visfatin concentrations
were determined in 80 normal pregnant women at 10–12,
24–26 and 34–36 weeks of gestation. During the first
trimester, visfatin concentrations were negatively corre-
lated with percentage of fat mass and hip circumference.
However, during the second and third trimesters, serum
concentrations of this adipokine were not correlated with
these surrogate markers of adipose tissue quantity. The
authors suggested that the progressive increase in insulin
resistance with advancing gestation can be compensat-
ed by a sustained increase of visfatin secretion by the
adipose tissue w125x. Fasshauer et al. w50x reported that
during the third-trimester, women with intrauterine
growth restriction (ns18) had a higher mean maternal
plasma visfatin concentration than those with an AGA
neonate (ns10). The same group reported that patients
with preeclampsia in the third-trimester (ns15) had a
higher mean maternal serum visfatin concentration than
normal pregnant women (ns20) w52x and that maternal
circulating visfatin was negatively correlated with HOMA-
IR, but not with maternal age or BMI w52x.
The association between maternal plasma visfatin
concentrations and gestational diabetes mellitus We
report herein that GDM is independently associated with
increased maternal plasma visfatin concentrations. Stud-
ies regarding maternal circulating visfatin in patients with
GDM are scant and inconsistent: both increased w101,
112x and decreased w34, 71x maternal visfatin concentra-
tions were reported. Our findings are in agreement with
those of Krzyanowska et al. w101x who reported a higher
maternal circulating visfatin in 64 patients with GDM than
in 30, mostly overweight, normal pregnant women at
28–30 weeks of gestation. Subsequently, Lewandowski
et al. w112x reported higher maternal visfatin concentra-
tions in 16 patients with GDM compared to 20 normal
pregnant women at 28 weeks of gestation. In contrast,
Chan et al. w34x demonstrated that patients with GDM
(ns20) in the late second trimester have a lower mean
visfatin serum concentration than normal pregnant wom-
en (ns20). Haider et al. w71x reported similar results in 10
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patients with GDM and 10 aged-matched controls at the
same gestational age (24–28 weeks). Differences in study
design may contribute to explain the differences among
studies. In particular, the number of subjects, gestational
age at enrolment, differences in BMI and neonatal birth
weights, differ between the studies.
The association between maternal plasma visfatin
concentrations and neonatal birthweight The inde-
pendent association between the delivery of an LGA
neonate and elevated maternal plasma visfatin concen-
trations is a novel finding. Previous reports have under-
scored the association between fetal growth restriction
(FGR) and increased maternal circulating visfatin. Fass-
hauer et al. w50x reported that mean plasma maternal vis-
fatin in the third trimester is higher in patients with FGR
than those with an AGA newborn. This finding was cor-
roborated by Malamitsi-Puchner et al. w120x. Of interest,
in the latter study, cord blood visfatin concentrations did
not differ between SGA and AGA neonates w120x. The
same group w121x reported that among patients with a
normal pregnancy and an AGA neonate, the mean cord
blood visfatin concentration was similar and positively
correlated with the mean maternal visfatin concentration;
furthermore, the mean cord blood visfatin concentration
was positively correlated with neonatal birthweight.
Based on these findings, the authors proposed that a
passive transplacental transfer of visfatin is probable
w120, 121x. Lo´pez-Bermejo et al. w117x reported a nega-
tive association between cord blood visfatin concentra-
tions and indices of fetal size only in mothers who
smoked, indicating that cord blood visfatin concentra-
tions may be, in part, under the regulation of maternal
factors. Taken together, these findings suggest that vis-
fatin has a role in the metabolic crosstalk between mater-
nal and fetal compartments. The strong association
reported herein, between the delivery of an LGA neonate
and elevated maternal plasma visfatin concentrations in
mothers with and without GDM further support this
hypothesis.
Visfatin concentrations in GDM and LGA neonate:
maternal metabolic status vis-a`-vis neonatal
birthweight Several explanations can account for the
association of increased maternal plasma visfatin con-
centration and GDM or the delivery of an LGA neonate:
1. Insulin resistance and impaired glucose metabolism in
women with GDM and/or LGA neonate: Insulin resis-
tance is accompanied by increased visfatin produc-
tion and/or secretion. Indeed, polymorphysms in the
visfatin gene w204x are associated with insulin resis-
tance and type-2 DM. In vivo clamp studies in
humans demonstrated that hyperglycemia increases
circulating visfatin concentrations w73x. Moreover, cir-
culating visfatin concentrations in patients with type-
2 DM are higher than in normal subjects w36, 53, 171x.
Given the insulin-mimic effect of visfatin, it has been
proposed that the increased concentrations of this
hormone in the context of insulin resistance, reflect a
compensatory mechanism aimed at ameliorating the
functional consequences of insulin deficiency w116x.
Collectively, these reports suggest an association
between insulin resistance and elevated visfatin. This
explanation can also be applicable, in part, to women
with an LGA neonate and without GDM since minor
abnormalities of glucose metabolism, even in the
absence GDM, have been implicated in patients with
neonatal overgrowth w92, 108, 111, 115, 130, 200x.
2. Overdistention of fetal membranes in patients with an
LGA neonate: In vitro studies have established a caus-
ality between stretching of human fetal membranes
and increased expression, production, and secretion
of visfatin w95, 142, 143, 149, 150x. Indeed, the vis-
fatin gene is up-regulated in response to stretching of
human fetal membranes w142, 143x. Moreover, visfatin
has been shown to be secreted from amniotic epithe-
lial-like cell line w150x. Recently, it has been demon-
strated that both expression and secretion of visfatin
increases after prolonged stretching of the fetal mem-
branes w95x. Consistently, an increased immuno-
staining for visfatin was demonstrated in the amnion
of twins and triplets w95x. Thus, it is tempting to spec-
ulate that the increased maternal plasma visfatin con-
centrations are derived, in part, from the stretched
fetal membranes of women with LGA fetuses. In addi-
tion, expression of visfatin in human placenta have
been reported w170x; thus, an increased secretion of
visfatin from larger placentas of LGA fetuses can also
account for our findings.
Collectively, transplacental transport, increased pla-
cental mass, and overdistation of fetal membranes may
account for the increase in maternal plasma visfatin con-
centrations in pregnant women with an LGA neonate.
Disparity in circulating maternal visfatin between
normal and overweight/obese pregnant women – the
role of maternal metabolic state and neonatal
weight As opposed to overweight/obese pregnant
women, those with a normal BMI had a comparable
median maternal visfatin concentration, regardless of
their metabolic state (GDM) or neonatal birthweight. Con-
sistent with our findings, Tsiotra et al. w188x reported that
visfatin mRNA expression from human peripheral mono-
cyte-enriched mononuclear cells is significantly elevated
in type-2 diabetic women, compared to healthy control
women, independently of the presence of overweight/
obesity.
The association between circulating visfatin and over-
weight/obesity is still under debate. Several studies
argued in favor of this association: serum visfatin con-
centration correlates with the amount of visceral fat
depot w171x, waist-to-hip ratio w36x, and BMI w19, 35, 113,
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171x. However, these reports were challenged by other
investigators who failed to find a positive correlation
between circulating visfatin and either visceral fat mass
w19x or BMI w36, 46, 50, 53, 87, 102, 122, 175, 183, 203x.
Currently, the exact physiologic and pathophysiologic
role of visfatin is not fully elucidated, as reflected from
this inconsistency in the literature. In the present study,
first trimester BMI was not independently associatedwith
maternal plasma visfatin concentrations after correction
for confounding factors. Thus, a cause and effect rela-
tionship between BMI and maternal circulating visfatin
concentrations data cannot be discerned. However, we
were able to extend the abovementioned observations by
demonstrating that the similarity between circulating
maternal visfatin in normal and overweight women is
unvaried even in the presence of GDM and/or LGA
neonate.
Conclusion
The linkage between increased maternal circulating vis-
fatin and the presence of GDM or delivery of an LGA
neonate support the hypothesis that perturbation of adi-
pokines homeostasis plays a role in the pathophysiology
of GDM and excess fetal growth.
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